Elicio Therapeutics Welcomes Preetam Shah as Chief Strategy and Financial Officer

Elicio Therapeutics (Nasdaq: ELTX) has named Dr. Preetam Shah as its new Chief Strategy and Financial Officer, bringing extensive experience in corporate finance, strategy, and business development. Dr. Shah has held leadership roles at several publicly traded biotech firms, including Cidara Therapeutics and Brainstorm Cell Therapeutics. His expertise in fundraising, M&A transactions, and strategic growth positions Elicio for continued success as it advances its immunotherapy pipeline, particularly the ELI-002 program for cancer treatment.

Dr. Shah expressed excitement about joining Elicio ahead of its key Phase 2 AMPLIFY-7P trial milestone, emphasizing the company’s strong leadership and promising early data. CEO Robert Connelly highlighted Shah’s financial acumen and biotech industry insight as pivotal for Elicio’s next growth phase. With this appointment, Elicio aims to strengthen its financial strategy while accelerating efforts to bring its cancer immunotherapies to market, offering new hope for patients worldwide.